Indictment — No. 1:20-cr-00278 (Dkt. 1, D.D.C.)

Summary

A grand jury Indictment in United States of America v. Keith Berman, Case 1:20-cr-00278-TNM, in the U.S. District Court for the District of Columbia, filed December 15, 2020 as Document 1, citing securities fraud provisions and 18 U.S.C. §§ 1001 & 2. It alleges that Berman, Chief Executive Officer and sole director of Decision Diagnostics Corp., made materially false public statements about a COVID-19 blood test using impedance technology to raise the company share price. It alleges that press releases on or about March 3 and 4, 2020 claimed a result in 15 seconds, and that Vendor 1, a technical advisor, told Berman it could not use impedance technology to test blood for COVID-19. It also alleges that Berman used over $360,000 in company funds for personal webcam chats while telling investors he received no cash compensation. The signature block names Trial Attorney Christopher Fenton.

Summary drafted by a model from the text of the original file linked on this page and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used